Wegovy Stomach Paralysis & Vision Loss Lawsuit – Status

Wegovy, the semaglutide drug made by Novo Nordisk, is named in lawsuits over stomach paralysis, also called gastroparesis, and sudden vision loss from NAION. Plaintiffs say the drug caused these injuries. The companies deny it. Individual lawsuits are centralized in two MDLs before Judge Karen S. Marston in the Eastern District of Pennsylvania. MDL No. 3094 covers gastrointestinal injuries. MDL No. 3163 covers NAION and began December 15, 2025. No settlement has been announced. The defendants are Novo Nordisk and Eli Lilly. Anyone who took Wegovy and developed these injuries may want a lawyer to review their records, because filing deadlines can end a claim.

Latest Wegovy Lawsuit Updates

September 14, 2026: Rule 702 Hearing Set in MDL 3094

The U.S. District Court for the Eastern District of Pennsylvania set a Rule 702 evidentiary hearing in the litigation over Wegovy and other GLP-1 drugs. It was scheduled for September 14 through September 18, 2026 [1]. Judge Karen S. Marston set the hearing to cover Cross Cutting Issues 2 and 3 in MDL No. 3094. Novo Nordisk and Eli Lilly and Company deny the allegations.

February 5, 2026: UK MHRA Issues NAION Safety Update

The UK Medicines and Healthcare products Regulatory Agency published a Drug Safety Update on semaglutide. It is the drug in Wegovy, Ozempic and Rybelsus. NAION has been very rarely reported in association with semaglutide, the update said [2]. The update says patients reporting sudden vision loss should be urgently referred for an eye examination. NAION typically causes sudden, painless vision loss in one eye.

December 15, 2025: Panel Creates NAION MDL 3163

The Judicial Panel on Multidistrict Litigation centralized 21 NAION actions as MDL No. 3163. They went to Judge Marston [3]. The panel was also notified of nine related actions, which are potential tag-along cases. Some plaintiffs allege both NAION and the gastrointestinal injuries at issue in MDL No. 3094.

August 15, 2025: Judge Rules on Gastric Emptying Studies

In an August 15, 2025 memorandum in MDL No. 3094, Judge Marston ruled that drug-induced gastroparesis claims need a properly performed gastric emptying study at diagnosis. It had to confirm delayed emptying [4]. The memorandum, Document 467, says the MDL then included more than 2,400 cases. It resolves Rule 702 motions on Issue 1.

August 13, 2025: Ohio Study Reports NAION Cases

Fox News reported on a JAMA study by Ohio-based researchers of people with type 2 diabetes. Of more than 159,000 participants, 35 developed NAION, compared with 19 in the comparison group [5]. The researchers described a modest risk with semaglutide and tirzepatide. An ophthalmologist told Fox that these are associations rather than causations.

June 9, 2025: Europe’s Safety Committee Calls NAION Very Rare

Eyewire reported that the European Medicines Agency safety committee (PRAC) concluded NAION is a very rare side effect of semaglutide. It may affect up to 1 in 10,000 patients [6]. The report says several large epidemiological studies link semaglutide use in adults with type 2 diabetes to roughly a twofold increased risk of NAION.

December 12, 2024: Saxenda Added to MDL 3094

The panel transferred the Wolfe action into MDL No. 3094. That extended the MDL to Saxenda actions. The panel’s order is Document 272 [7]. The order describes Ozempic, Wegovy and Rybelsus as drugs that each contain semaglutide and are made by the Novo Nordisk defendants.

October 17, 2024: Court Splits Discovery in MDL 3094

Judge Marston’s memorandum noted that the court had granted bifurcated discovery, with early motion practice on two cross cutting issues [8]. The two issues are gastroparesis diagnostic testing, and preemption and adequacy of warnings. The court issued the memorandum as Document 276 in MDL No. 3094.

October 5, 2023: JAMA Study Links GLP-1 Drugs to Stomach Paralysis

University of British Columbia researchers published a study in JAMA. It linked GLP-1 drugs to a higher risk of stomach paralysis, pancreatitis and bowel obstruction, Fox News reported [9]. The study covered approximately 16 million U.S. patients prescribed semaglutide or liraglutide medications between 2006 and 2020. Those taking a GLP-1 agonist were 3.67 times more likely to develop stomach paralysis than those taking bupropion-naltrexone.

August 2, 2023: Louisiana Woman Sues over Ozempic and Mounjaro

A Louisiana woman, Jaclyn Bjorklund, sued Novo Nordisk and Eli Lilly over gastrointestinal injuries she attributed to Ozempic and Mounjaro, Fox 5 reported [10]. The complaint alleged severe and permanent injuries and a failure to warn. It does not say whether she was diagnosed with gastroparesis, and it does not involve Wegovy.

June 4, 2021: FDA First Approves Wegovy

The FDA first approved Wegovy (semaglutide) on June 4, 2021 to treat adults with obesity. Novo Nordisk makes the drug [11]. Wegovy is now named with Ozempic, Rybelsus and Saxenda in the GLP-1 receptor agonist litigation.

What Is Gastroparesis?

According to the National Institute of Diabetes and Digestive and Kidney Diseases, gastroparesis, also called delayed gastric emptying, is a disorder. It slows or stops the movement of food from the stomach to the small intestine [12]. Gastroparesis is the main injury alleged in MDL No. 3094. Plaintiffs there allege that GLP-1 drugs such as Wegovy caused it.

Who May Be Affected?

People who used Wegovy, Ozempic, Rybelsus, Saxenda, Trulicity or Mounjaro fall within MDL No. 3094. That applies if they allege a gastrointestinal injury. NAION claims go to MDL No. 3163, which names Ozempic, Wegovy, Saxenda and Trulicity. Those cases involve sudden vision loss rather than stomach injuries. In her August 15, 2025 memorandum, Judge Marston wrote that most plaintiffs claim permanent or persistent gastroparesis. She also said some plaintiffs will be unable to prove it because no properly performed gastric emptying study backs their diagnosis. ConsumerAffairs reported on December 23, 2025 that nearly 3,000 cases were pending in MDL No. 3094 [13]. No settlement or bellwether trial date has been announced in either MDL. Each claim is different, and qualifying takes an individual legal review. Schmidt & Clark can review your situation. People who used Ozempic can also read our Ozempic stomach paralysis lawsuit page.

Reported Injuries or Damages

Plaintiffs in MDL No. 3094 allege gastroparesis, ileus, intestinal obstruction and other gastrointestinal injury. The court’s October 2024 memorandum also lists cholecystitis and severe nausea and vomiting. Plaintiffs in MDL No. 3163 allege NAION. It is an optic nerve condition that can cause sudden vision loss. These are complaint allegations. No court has decided that these drugs caused the injuries. Healio reported on two JAMA Ophthalmology analyses from a talk at Academy 2026 [14]. Hathaway and colleagues found a four- to sevenfold greater NAION risk with semaglutide in more than 16,000 patients. The 2023 British Columbia stomach paralysis study could not assess whether the condition was temporary or permanent. Cai and colleagues used 14 databases covering more than 37 million patients and found a modest increase in NAION, smaller than previously reported.

Recall and Regulatory Background

The FDA’s Wegovy label says Wegovy is not recommended in patients with severe gastroparesis. It also warns of pulmonary aspiration during general anesthesia or deep sedation [15]. In weight-reduction trials, severe gastrointestinal adverse reactions were reported in 4.1% of Wegovy patients and 0.9% of placebo patients. The US label, revised in August 2025, does not list NAION.

Evidence to Preserve

These records can help a lawyer review what happened to you:

• Prescription, pharmacy and dosage records for Wegovy or other GLP-1 drugs
• Dates of your first and last use of each drug
• Gastric emptying study results (scintigraphy, breath test or wireless motility capsule) and endoscopy reports
• Diagnosis and treatment records for gastroparesis, ileus or intestinal obstruction
• Eye exam records from your eye doctor for NAION
• Hospital and emergency room bills
• A symptom diary and photographs
• Messages with your doctors and the drug maker

Filing Deadlines

Injury claims have filing deadlines set by state law. Which one applies depends on where you live, so the same injury can face different time limits in different states. It also depends on when your injury and its diagnosis happened. Missing a deadline can end a claim whatever the facts show. A lawyer can check the deadline that applies to your specific situation, so ask promptly and bring your medical and prescription records.

Frequently Asked Questions

Can You Sue for Wegovy Stomach Paralysis?

You can sue for Wegovy stomach paralysis only if your facts support a claim. People have filed product liability lawsuits over GLP-1 drugs, including Wegovy. Novo Nordisk has said gastrointestinal events are well-known side effects of the GLP-1 class and are noted in the label.

Is There a Wegovy Class Action Lawsuit?

There is no Wegovy class action lawsuit. The cases are personal injury actions with individual plaintiffs, coordinated for pretrial proceedings. The 21 NAION actions came from the District of New Jersey, the Eastern District of Pennsylvania and the Northern District of Texas.

Does Wegovy Cause Gastroparesis?

Research links Wegovy and similar drugs to gastroparesis, but no court has found that Wegovy causes it. The University of British Columbia authors of the 2023 JAMA study could not look at individual GLP-1 drugs. Co-author Dr. Mahyar Etminan called the risk probably a class effect.

What Does the Research Say About Wegovy and Vision Loss?

Research on Wegovy and vision loss points to an association without a proven cause. A 2025 Ohio study reported by Fox News did not observe a statistically significant difference in NAION. Novo Nordisk says its analysis of trials does not suggest a causal relationship.

References

1. https://www.paed.uscourts.gov/node/2669
2. https://assets.publishing.service.gov.uk/media/69847cb7468d351e1406b4d2/DSU_-_Semaglutide_and_NAION_-_5_Feb_2026.pdf
3. https://www.jpml.uscourts.gov/sites/jpml/files/MDL-3163-Transfer_Order-12-25.pdf
4. https://assets.alm.com/49/40/6783287f42c0938c3e0887e31822/opinion-on-issue-1-rule-702-motions-8-15-2025.pdf
5. https://www.foxnews.com/health/popular-weight-loss-drugs-linked-sudden-vision-loss-research-suggests
6. https://eyewire.news/news/ema-review-finds-rare-risk-of-vision-loss-associated-with-semaglutide-medicines
7. https://www.jpml.uscourts.gov/sites/jpml/files/MDL-3094-Transfer_Order-12-24.pdf
8. https://www.govinfo.gov/content/pkg/USCOURTS-paed-2_24-md-03094/pdf/USCOURTS-paed-2_24-md-03094-0.pdf
9. https://www.foxnews.com/health/ozempic-wegovy-may-be-linked-stomach-paralysis-other-digestive-issues-large-scale-study.amp
10. https://www.fox5vegas.com/2023/08/03/woman-sues-drug-makers-ozempic-mounjaro-over-severe-gastrointestinal-issues
11. https://www.drugs.com/history/wegovy.html
12. https://www.niddk.nih.gov/health-information/digestive-diseases/gastroparesis/definition-facts
13. https://www.consumeraffairs.com/news/nearly-3000-plaintiffs-sue-over-glp-1-drug-side-effects-122325.html
14. https://www.healio.com/news/optometry/20261002/glp1s-may-be-linked-to-vision-loss-but-overall-risk-very-very-low
15. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf